Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
CHMP recommends EU approval of Enhertu for previously treated HER2-positive metastatic Solid tumours
29 May 2026
Regulatory
Gilead receives CHMP positive opinion for Trodelvy in 1L metastatic TNBC patients ineligible for PD-(L)1...
29 May 2026
Regulatory
Sino Biopharmaceuticals CLDN18.2 ADC LM-302 granted Priority Review with China approval expected
29 May 2026
Regulatory
PADCEV in combination with Keytruda receives positive CHMP opinion for the treatment of patients with...
22 May 2026
Regulatory
Astellas Pharma sNDA in Japan for PADCEV in combination with Keytruda for cisplatin-eligible patients with...
15 May 2026
Regulatory
The sNDA for Sacituzumab Tirumotecan in combination with Pembrolizumab as 1L treatment for PD-L1 positive...
15 May 2026

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id